BioPharmX

@biopharmx

BioPharmX Corporation (NYSE American: ) is a specialty pharmaceutical company focused on optimizing drug delivery to benefit dermatology patients worldwide

Vrijeme pridruživanja: veljača 2014.

Tweetovi

Blokirali ste korisnika/cu @biopharmx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @biopharmx

  1. 9. ruj 2019.

    BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update

    Poništi
  2. 18. srp 2019.

    Our new COO Mr. Bosacki previously served as President and CEO of Lautus Pharmaceuticals, a privately held pharmaceutical company focused on the and aesthetics markets. Learn more about his experience here:

    Poništi
  3. 17. srp 2019.

    Our new COO Mr. Bosacki previously served as Senior Vice President and General Counsel under BioPharmX CEO, Dr. David S. Tierney, at Oceana Therapeutics

    Poništi
  4. 16. srp 2019.

    BioPharmX today announces the appointment of Steven M. Bosacki, a 20 year pharmaceutical industry veteran, as its Chief Operating Officer

    Poništi
  5. 27. lip 2019.

    BPX-04 was well-tolerated in a Phase 2b trial for moderate-to-severe papulopustular and the efficacy and safety profile observed supports advancement into Phase 3

    Poništi
  6. 26. lip 2019.

    "We are pleased with the overwhelmingly positive outcome on both the primary and secondary efficacy measures as well as the confirmation of the safety and cutaneous tolerability of our minocycline gel formulation," commented CEO

    Poništi
  7. 25. lip 2019.

    BPX-04 successfully met both the primary and secondary endpoints of the trial in demonstrating a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear

    Poništi
  8. 25. lip 2019.

    BioPharmX today announced positive results from its Phase 2b clinical trial of BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular

    Poništi
  9. 13. lip 2019.

    Approximately 40 to 50 million Americans suffer from vulgaris. We are developing BPX-01, a topical version of minocycline, for these patients. Learn more:

    Poništi
  10. 11. lip 2019.

    BioPharmX Reports Fiscal First Quarter 2020 Financial Results

    Poništi
  11. 11. lip 2019.

    is the most common skin condition that people experience. Most people develop acne to some degree during their lifetime. Understand the underlying causes of acne:

    Poništi
  12. 10. lip 2019.

    In a Phase 2b study, BPX-01 demonstrated a 58% reduction in inflammatory acne lesions. Learn about our development of a novel, proprietary topical minocycline gel for vulgaris:

    Poništi
  13. 6. lip 2019.

    BPX-04 was designed to deliver minocycline topically for patients looking to minimize systemic exposure to antibiotics. Learn more about the development program here:

    Poništi
  14. 5. lip 2019.

    is a common skin disease that can cause redness, swelling, and acne-like breakouts. provides an overview:

    Poništi
  15. 3. lip 2019.

    Our HyantX™ delivery system was designed to minimize the dosage required of a drug through enhanced targeted delivery, thereby limiting skin irritation associated with excess drug on the skin. Learn more from our CEO's latest presentation:

    Poništi
  16. 31. svi 2019.

    BioPharmX is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal

    Poništi
  17. 30. svi 2019.

    is a chronic dermatologic condition characterized by redness, stinging & inflammatory lesions primarily on the face. Learn more about our Ph 2b trial of BPX-04 which we anticipate reporting topline efficacy & safety results in July 2019

    Poništi
  18. 28. svi 2019.

    We've completed patient visits in our Phase 2b trial of BPX-04 for , a chronic dermatologic condition characterized by redness, stinging and inflammatory lesions primarily on the face

    Poništi
  19. 23. svi 2019.

    BPX-04 is a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular that leverages our HyantX™ topical delivery system. We recently announced our last patient visit in a Phase 2b trial:

    Poništi
  20. 23. svi 2019.

    "We are pleased to announce this important milestone and look forward to reporting topline results from the study in early July 2019, subject to successful database lock and results validation," said BioPharmX CEO

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·